In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 1157-1159

  Pelaez T ^a   Alcala L ^a   Alonso, R ^a   Martin Lopez A ^a   Garcia Arias V ^a   Marin M ^a   Bouza, E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; RAMOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

CLOSTRIDIUM DIFFICILE; DEPSIPEPTIDES; DRUG RESISTANCE, BACTERIAL; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN;

EID: 14744270608     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.1157-1159.2005     Document Type: Article

References (25)

1. Bartlett, J. G. 2002. Antibiotic-associated diarrhea. N. Engl. J. Med. 346:334-339.
2. Biavasco, F., E. Manso, and P. E. Varaldo. 1991. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 35:195-197.
3. Bouza, E., T. Peláez, R. Alonso, P. Catalán, P. Muñoz, and M. Rodríguez-Creixems. 2001. "Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J. Hosp. Infect. 48:233-237.
4. Brazier, J. S., W. N. Fawley, J. Freeman, and M. H. Wilcox. 2001. Reduced susceptibility of Clostridium difficile to metronidazole. J. Antimicrob. Chemother. 48:741.
5. Citron, D. M., C. V. Merriam, K. L. Tyrrell, Y. A. Warren, H. Fernández, and E. J. C. Goldstein. 2003. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob. Agents Chemother. 47:2334-2338.
6. Cudic, P., J. K. Kranz, D. C. Behenna, et al. 2002. Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation. Proc. Natl. Acad. Sci. USA 99:7384-7389.
7. Dworczynski, A., B. Sokó, and F. Meisel. 1991. Antibiotic resistance of C. difficile isolates. Cytobios 64:149-153.
8. Freeman, J., J. Stott, S. Baines, W. Fawley, and M. Wilcox. 2003. Surveillance for resistance to metronidazole, vancomycin or ramoplanin in genotypically distinct and clonal Clostridium difficile strains, abstr. E-2190. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
9. Gerding, D. N. 1989. Disease associated with Clostridium difficile infection. Ann. Intern. Med. 110:255-257.
10. Gumerlock, P. H., Y. J. Tang, F. J. Meyers, and J. Silva, Jr. 1991. Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces. Rev. Infect. Dis. 13:1053-1060.
11. Jabes, D., C. Candiani, S. Riva, and G. Mosconi. 2003. Superior efficacy of short treatment duration of ramoplanin over vancomycin in the hamster model of C. difficile associated colitis, abstr. B-328. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
12. Jones, R. N., and A. L. Barry. 1989. In vitro evaluation of ramoplanin (A 16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn. Microbiol. Infect. Dis. 3:279-282.
13. Kato, N., C. Y. Ou, H. Kato, S. L. Bartley, V. K. Brown, V. R. Dowell, Jr., and K. Ueno. 1991. Identification of toxigenic Clostridium difficile by the polymerase chain reaction. J. Clin. Microbiol. 29:33-37.
14. Kelly, C. P., C. Pothoulakis, and J. T. LaMont. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262.
15. Montecalvo, M. A. 2003. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients. J. Antimicrob. Chemother. 51(Suppl. 3):131-135.
16. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 2003. Manual of clinical-microbiology, 8th ed. ASM Press, Washington, D.C.
17. Mylonakis, E., E. T. Ryan, and S. B. Calderwood. 2000. Clostridium difficile-associated diarrhea: a review. Arch. Intern. Med. 161:525-533.
18. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 5th ed. M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
19. Peláez, T., L. Alcalá, R. Alonso, M. Rodríguez- Créixems, J. M. García-Lechuz, and E. Bouza. 2002. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46:1647-1650.
20. Rifkin, G. D., F. R. Fekety, and J. Silva, Jr. 1977. Antibiotic-induced colitis: implication of a toxin neutralized by Clostridium sordellii antitoxin. Lancet ii:1103-1106.
21. Somner, E. A., and P. E. Reynolds. 1990. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 34:413-419.
22. Thelestam, M., and M. Bronnegard. 1980. Interaction of cytopathogenic toxin from Clostridium difficile with cells in tissue culture. Scand. J. Infect. Dis. Suppl. 1980(Suppl. 22):16-29.
23. Wolfhagen, M. J., A. C. Fluit, R. Torensma, M. J. Poppelier, and J. Verhoef. 1994. Rapid detection of toxigenic Clostridium difficile in fecal samples by magnetic immuno PCR assay. J. Clin. Microbiol. 32:1629-1633.
24. Wong, M. T., C. A. Kauffman, H. C. Standiford. et al. 2001. Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolidepsipeptide, ramoplanin. Clin. Infect. Dis. 33:1476-1482.
25. Wong, S. S., P. C. Woo, W. K. Luk, and K. Y. Yuen. 1999. Susceptibility testing of C. difficile against metronidazole and vancomycin by disk diffusion and E-test. Diagn. Microbiol. Infect. Dis. 34:1-6.